iRhythm Technologies, Inc. Stock News

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $224.2 million, a 20.1% increase compared to second quarter 202...

iRhythm Holdings on Monday reported unauthorized activity involving data maintained on some third-party applications last week, but said ​it has not identified any impact on products, ‌patient safety or medical device systems from the cyber attack.

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that the company will be participating in the following investor conferences.

SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026.

SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2026 Health Care Conference. iRhythm's management is scheduled to present on Wednesday, May 13, 2...

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio ® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations. 1-2 Findings raise important c...